header image

Noticias Recientes

Wolfgang Marguerre donates €250,000 to University Hospital Heidelberg to support innovation in medical training

22.10.2015

Octapharma AG Chairman Wolfgang Marguerre has donated €250,000 to University Hospital Heidelberg’s oral and maxillofacial surgery clinic to support innovation in medical training.   The clinic’s 26 doctors treat 30,000...

Octapharma AG invests €80 million to acquire an exclusive worldwide license to certain IP of Glycotope’s recombinant technology and to become a minority shareholder of Glycotope GmbH Berlin

07.10.2015

Lachen, Switzerland, October 8th, 2015: Octapharma AG invests €80 million to acquire an exclusive worldwide license to certain IP of Glycotope’s recombinant technology and to become a minority shareholder of Glycotope GmbH...

FDA Approves Octapharma’s NUWIQ® for the Treatment of Adults and Children with Hemophilia A

14.09.2015

HOBOKEN, N.J. September 15th, 2015: Octapharma USA today announced the U.S. Food and Drug Administration (FDA) has approved NUWIQ®, Antihemophilic Factor (Recombinant), an intravenous therapy for adults and children living with...

Octapharma helping to change the paradigm in Portuguese plasma

19.08.2015

LACHEN, August 19th 2015: Portugal will receive a continuous flow of blood products from Portuguese plasma for the first time as a result of an historic self-sufficiency initiative supported by Octapharma. Four hospitals in...

Octapharma USA: FDA Approves WILATE® License Supplement – Perioperative Management of Bleeding in Patients with von Willebrand Disease

12.08.2015

HOBOKEN, N.J. August 13th, 2015 – Octapharma USA today announced the U.S. Food and Drug Administration (FDA) has approved revised product labeling for WILATE®  [von Willebrand Factor/Coagulation Factor VIII Complex (Human)]...

Publication of Clinical Data Demonstrating Successful Immune Tolerance Induction (ITI) with OCTANATE® in Severe Haemophilia A in "Haemophilia"

04.08.2015

Lachen, Switzerland August 4th 2015 - Octapharma announces the publication in Haemophilia of data reporting on successful Immune Tolerance Induction (ITI) with OCTANATE® in a large cohort of Haemophilia A patients with FVIII...

Octapharma sponsors symposium ‘Haemophilia A: Individualised solutions to global challenges’ at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Toronto, Canada

13.07.2015

LACHEN, Switzerland, July 13th, 2015 – Octapharma sponsored the symposium ‘Haemophilia A: Individualised solutions to global challenges’ at the ISTH Congress in Toronto, Canada, on June 23rd, 2015. The symposium provided an...

Muestra Resultados de 1 a 7 11